President Trump previously directed the Justice Department to reschedule the drug in a December executive order.

If the FDA approves a drug for a neglected tropical disease, the company gets a voucher that accelerates review of another drug. This remains controversial.

The US Food and Drug Administration (FDA) has called on its Pharmacy Compounding Advisory Committee to discuss whether a ...

Researchers developed a computational “virtual twin” that uses patient-specific clinical data to predict how the cancer drug ...